Berlin Heals Holding AG, a MedTech company focused on transformative therapies for heart failure, announced the successful closing of a new financing round, raising over $10 million from a combination of existing shareholders and new investors. The capital will be used to further develop the company’s cardiac microcurrent technology and expand its clinical research program.
The company has developed a novel therapeutic approach for heart failure based on its proprietary implantable device, C-MIC (Cardiac Microcurrent). The system has demonstrated strong clinical outcomes to date, and Berlin Heals is continuing to build on that evidence base. Updated clinical data are expected to be presented at major cardiology conferences this year, alongside new scientific publications.
Berlin Heals is now entering its next phase of innovation, with a focus on less invasive implantation techniques and enhanced device designs to broaden patient eligibility and simplify future adoption. The newly secured funding will also support expanding indications to broader patient populations and initiating larger double-blind trials in preparation for an FDA investigational device exemption submission.
The company has previously reported sustained functional and quality-of-life improvements in patients with dilated cardiomyopathy treated with C-MIC. Long-term follow-up data from early studies continue to reinforce confidence in the therapy’s durability and support its clinical and regulatory strategy.
Separately, Berlin Heals also announced that Rob ten Hoedt has been welcomed as the new Chairman of the Board.
KEY QUOTES
“Closing this financing round marks an important milestone for us. We are deeply thankful to our Co-Founder of Berlin Heals Holding Ltd. and the Member of the Board – Marko Bagaric for achieving another impressive round of financing. His long-term vision and dedication to this company is crucial for the trust of our long-standing shareholders and welcoming new investors who share our vision. Having this strong background and support, together with our clinical data, we now have even more confidence to move into less invasive solutions that could significantly expand the impact of our therapy. This funding allows us as well to take decisive steps toward global commercialization.”
John Brumfield, Chief Executive Office Of Berlin Heals Holding
“Heart failure remains an area of tremendous unmet medical need. Having followed the growth of Berlin Heals, I am convinced that this technology has the potential to redefine how we treat heart failure patients. This financing enables the company to translate its innovation into a therapy that can reach many more patients worldwide and influence greatly their quality of life.”
Rob ten Hoedt, Board Chairman Of Berlin Heals Holding AG
